Healthcare / Medical DevicesNasdaqGS
$7.35
-0.43 (-5.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 17%
FCF escenarios
weak_data · normalized FCF $13.0M · quality 26.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$706M
P/E
N/A
•EV/EBITDA
10.1x
↓ROE
-8.0%
↓Gross Margin
15.4%
↓Debt/Equity
1.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
—
FCF margin
-0.6%
FCF / Net income
0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.02B · net income $-47.1M · FCF $-6.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $1.02B | $1.02B | $948.9M | $935.9M |
| Net Income | $-47.1M | $-47.1M | $-94.1M | $-122.2M |
| EBITDA | $141.7M | $141.7M | $114.0M | $94.5M |
| EPS | -0.66 | -0.66 | -1.35 | -1.76 |
| Gross Margin | 15.4% | 15.4% | 10.1% | 10.6% |
| Operating Margin | 2.6% | 2.6% | -1.7% | -1.4% |
| Net Margin | -4.6% | -4.6% | -9.9% | -13.1% |
| Balance Sheet | ||||
| Debt/Equity | 1.64 | 1.64 | 8.10 | 6.58 |
| Current Ratio | 1.41 | 1.41 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-6.4M | $-6.4M | $13.0M | $13.5M |
| Returns | ||||
| ROE | -8.0% | -8.0% | -58.2% | -61.6% |
| Valuation | ||||
| EV/EBITDA | 10.06 | 10.06 | — | — |
| P/B | 0.89 | 0.89 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 7.8% | 7.8% | 1.4% | — |
| EPS Growth | 51.1% | 51.1% | 23.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.35 → -0.66
Residual
-60.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.